Discovery & development
Pipeline
Discovery and development
HER-2–V-001 ADC
HER-2 directed ADC with V-001 Payload for Breast Cancer with PIK3CA mutations & MDR
FDA Fast Track designation to
accelerate Phase 1/2A trials
EGFR–V-001 ADC
EGFR directed ADC with V-001 Payload for Triple Negative Breast Cancer with PIK3CA mutations & MDR
FDA Fast Track designation to
accelerate Phase 1/2A trials
V-001 Parenteral
Intravenous formulation for metastatic cancer with PIK3CA mutations & MDR
FDA Fast Track designation to
accelerate Phase 1/2A trials